First quarter 2023 results

First quarter 2023 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.

Featuring

Paul Hudson

Chief Executive Officer

Jean-Baptiste de Chatillon

Chief Financial Officer

Bill Sibold

Specialty Care

Olivier Charmeil

General Medicines

Dietmar Berger

Global Head of R&D ad interim

Thomas Triomphe

Vaccines

Julie van Ongevalle

Consumer Healthcare

Roy Papatheodorou

General Counsel

Highlights

We have started 2023 with strong results, delivering double-digit sales growth across our Specialty Care, Vaccines and Consumer Healthcare businesses. With two best in class launches this year and the acceleration of our early-mid stage pipeline, we are well underway.